Can GLP-1 receptor drugs help treat Parkinson's disease? Insights from a lixisenatide trial

Lixisenatide improved motor scores in Parkinson's disease patients under 60 years old after 12 months of treatment.

• The primary endpoint of motor changes was measured using the MDS-UPDRS part 3 scale.
• Statistical analysis showed a significant difference in motor scores between lixisenatide and placebo, but the clinical significance was not reached.
• Post hoc analysis indicated that younger patients (<60 years) experienced greater improvement in motor scores compared to older patients (≥60 years).
• No significant changes were observed in secondary or exploratory non-motor endpoints.
• The effects of lixisenatide on motor function may require long-term treatment to be clinically meaningful.

Simplified